The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2021 | CAR-T in myeloma: key players in the therapeutic landscape
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses CAR T-cell therapy for multiple myeloma. Although the multiple myeloma treatment landscape is rapidly evolving and the development of new therapies has greatly improved outcomes, patients with triple or penta-refractory disease still have limited treatment options. Recently, clinical trials investigating CAR T-cells for multiple myeloma have demonstrated promising clinical activity, showing unprecedented response rates in these heavily pre-treated patient population. Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are among several BCMA CAR T-cell products in later stages of clinical trials, and it is anticipated that they will be approved in 2021. Prof. Mohty believes that the whole treatment paradigm will see some significant changes in the next five years as CAR T-cells move into earlier lines of therapy. Additionally, Prof. Mohty highlights other immunotherapy strategies, such as BiTEs, as well as novel targets. This interview took place during the 3rd European CAR T-cell Meeting.
